There is also an ongoing phase II study to evaluate the therapeutical possibility of this molecule for breast cancer, comparing the efficacy with different drug doses against HER-2-positive and HER-2 low expression in cancer patients [106]. The gene discussed is ERBB2; the disease is breast carcinoma.